Review



deidentified clinformatics data mart database datasets  (Optum Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Optum Inc deidentified clinformatics data mart database datasets
    Study design. * The index date for the 1-dose and 2-dose cohorts was the date of receipt of the first and second RZV dose, respectively. The index date for unvaccinated patients corresponded to that of the vaccinated patients. Note: Propensity score matching was done at the index date. For each AID condition and sensitivity analyses, separate propensity scores and different sets of potential confounders were included. For stratified analysis with matched variables, individuals were matched on AID condition, age group, and medication category; then 1:3 matched on propensity scores with the list of covariates. Abbreviations: AID, autoimmune disease; CDM, Optum <t>Clinformatics®</t> Data Mart Database; HZ, herpes zoster; IR, incidence rate; non-RZV cohort, unvaccinated patients; RZV, adjuvanted recombinant zoster vaccine; RZV cohort, RZV-vaccinated patients; US, United States; VE, vaccine effectiveness; ZVL, live-attenuated varicella-zoster virus vaccine.
    Deidentified Clinformatics Data Mart Database Datasets, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/deidentified clinformatics data mart database datasets/product/Optum Inc
    Average 86 stars, based on 1 article reviews
    deidentified clinformatics data mart database datasets - by Bioz Stars, 2026-05
    86/100 stars

    Images

    1) Product Images from "Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases"

    Article Title: Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases

    Journal: The Journal of Infectious Diseases

    doi: 10.1093/infdis/jiaf395

    Study design. * The index date for the 1-dose and 2-dose cohorts was the date of receipt of the first and second RZV dose, respectively. The index date for unvaccinated patients corresponded to that of the vaccinated patients. Note: Propensity score matching was done at the index date. For each AID condition and sensitivity analyses, separate propensity scores and different sets of potential confounders were included. For stratified analysis with matched variables, individuals were matched on AID condition, age group, and medication category; then 1:3 matched on propensity scores with the list of covariates. Abbreviations: AID, autoimmune disease; CDM, Optum Clinformatics® Data Mart Database; HZ, herpes zoster; IR, incidence rate; non-RZV cohort, unvaccinated patients; RZV, adjuvanted recombinant zoster vaccine; RZV cohort, RZV-vaccinated patients; US, United States; VE, vaccine effectiveness; ZVL, live-attenuated varicella-zoster virus vaccine.
    Figure Legend Snippet: Study design. * The index date for the 1-dose and 2-dose cohorts was the date of receipt of the first and second RZV dose, respectively. The index date for unvaccinated patients corresponded to that of the vaccinated patients. Note: Propensity score matching was done at the index date. For each AID condition and sensitivity analyses, separate propensity scores and different sets of potential confounders were included. For stratified analysis with matched variables, individuals were matched on AID condition, age group, and medication category; then 1:3 matched on propensity scores with the list of covariates. Abbreviations: AID, autoimmune disease; CDM, Optum Clinformatics® Data Mart Database; HZ, herpes zoster; IR, incidence rate; non-RZV cohort, unvaccinated patients; RZV, adjuvanted recombinant zoster vaccine; RZV cohort, RZV-vaccinated patients; US, United States; VE, vaccine effectiveness; ZVL, live-attenuated varicella-zoster virus vaccine.

    Techniques Used: Recombinant, Virus



    Similar Products

    deidentified clinformatics data mart database datasets  (Optum Inc)
    86
    Optum Inc deidentified clinformatics data mart database datasets
    Study design. * The index date for the 1-dose and 2-dose cohorts was the date of receipt of the first and second RZV dose, respectively. The index date for unvaccinated patients corresponded to that of the vaccinated patients. Note: Propensity score matching was done at the index date. For each AID condition and sensitivity analyses, separate propensity scores and different sets of potential confounders were included. For stratified analysis with matched variables, individuals were matched on AID condition, age group, and medication category; then 1:3 matched on propensity scores with the list of covariates. Abbreviations: AID, autoimmune disease; CDM, Optum <t>Clinformatics®</t> Data Mart Database; HZ, herpes zoster; IR, incidence rate; non-RZV cohort, unvaccinated patients; RZV, adjuvanted recombinant zoster vaccine; RZV cohort, RZV-vaccinated patients; US, United States; VE, vaccine effectiveness; ZVL, live-attenuated varicella-zoster virus vaccine.
    Deidentified Clinformatics Data Mart Database Datasets, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/deidentified clinformatics data mart database datasets/product/Optum Inc
    Average 86 stars, based on 1 article reviews
    deidentified clinformatics data mart database datasets - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Study design. * The index date for the 1-dose and 2-dose cohorts was the date of receipt of the first and second RZV dose, respectively. The index date for unvaccinated patients corresponded to that of the vaccinated patients. Note: Propensity score matching was done at the index date. For each AID condition and sensitivity analyses, separate propensity scores and different sets of potential confounders were included. For stratified analysis with matched variables, individuals were matched on AID condition, age group, and medication category; then 1:3 matched on propensity scores with the list of covariates. Abbreviations: AID, autoimmune disease; CDM, Optum Clinformatics® Data Mart Database; HZ, herpes zoster; IR, incidence rate; non-RZV cohort, unvaccinated patients; RZV, adjuvanted recombinant zoster vaccine; RZV cohort, RZV-vaccinated patients; US, United States; VE, vaccine effectiveness; ZVL, live-attenuated varicella-zoster virus vaccine.

    Journal: The Journal of Infectious Diseases

    Article Title: Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases

    doi: 10.1093/infdis/jiaf395

    Figure Lengend Snippet: Study design. * The index date for the 1-dose and 2-dose cohorts was the date of receipt of the first and second RZV dose, respectively. The index date for unvaccinated patients corresponded to that of the vaccinated patients. Note: Propensity score matching was done at the index date. For each AID condition and sensitivity analyses, separate propensity scores and different sets of potential confounders were included. For stratified analysis with matched variables, individuals were matched on AID condition, age group, and medication category; then 1:3 matched on propensity scores with the list of covariates. Abbreviations: AID, autoimmune disease; CDM, Optum Clinformatics® Data Mart Database; HZ, herpes zoster; IR, incidence rate; non-RZV cohort, unvaccinated patients; RZV, adjuvanted recombinant zoster vaccine; RZV cohort, RZV-vaccinated patients; US, United States; VE, vaccine effectiveness; ZVL, live-attenuated varicella-zoster virus vaccine.

    Article Snippet: We conducted a retrospective matched cohort study using Optum's deidentified Clinformatics® Data Mart Database datasets from January 2018 to December 2021.

    Techniques: Recombinant, Virus